Targeting HSP90 is an attractive strategy in CLL as this could represent a therapeutic option to drug resistance in CLL associated with lesions in the ATM/TP53 pathway [25-27]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.